Company Description

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.

The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC).

Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026.

enGene Therapeutics Inc. is based in Montreal, Canada.

enGene Therapeutics Inc.

Country	Canada
Founded	1999
Industry	Biotechnology
Sector	Healthcare
Employees	82
CEO	Ronald H. Cooper

Contact Details

Address: 4868 Rue Levy, Suite 220 Montreal, QC H4R 2P1 Canada
Phone	514 332 4888
Website	engene.com

Stock Details

Ticker Symbol	ENGN
Exchange	NASDAQ
Share Class	Class A Shares
Fiscal Year	November - October
Reporting Currency	USD
CIK Code	1980845
CUSIP Number	29286X101
ISIN Number	CA29286X1015
SIC Code	2836

Key Executives

Name	Position
Ronald H. W. Cooper	President, Chief Executive Officer and Director
Dr. William J. Grossman M.D., Ph.D.	Interim Chief Medical Officer and Director
Dr. Anthony T. Cheung Ph.D.	Co-Founder and Chief Scientific Officer
Joan Connolly	Chief Technology Officer
Tara Place M.B.A.	Senior Vice President of Human Resources
Matthew Boyd	Chief Regulatory Officer
Jill Buck	Chief Development Officer
Amy Pott	Chief Global Commercialization Officer
Kathleen Richton	Vice President and Controller

Latest SEC Filings

Date	Type	Title
Jul 22, 2026	SCHEDULE 13G	Filing
Jul 17, 2026	8-K	Current Report
Jul 16, 2026	8-K	Current Report
Jun 18, 2026	8-K/A	[Amend] Current report
Jun 15, 2026	10-Q	Quarterly Report
Jun 15, 2026	8-K	Current Report
Jun 10, 2026	8-K	Current Report
May 15, 2026	SCHEDULE 13G/A	Filing
May 14, 2026	SCHEDULE 13G/A	Filing
May 13, 2026	SCHEDULE 13G	Filing

View All SEC Filings